Transcriptional effects of 1,25 dihydroxyvitamin D3 physiological and supra-physiological concentrations in breast cancer organotypic culture

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Milani, Cintia ^a   Katayama, Maria Lucia Hirata ^a   De Lyra, Eduardo Carneiro ^a,b   Welsh, JoEllen ^c   Campos, Laura Tojeiro ^a   Brentani, M Mitzi ^a   Maciel, Maria do Socorro ^d   Roela, Rosimeire Aparecida ^a   Del Valle, Paulo Roberto ^a   Góes, João Carlos Guedes Sampaio ^b   Nonogaki, Suely ^e   Tamura, Rodrigo Esaki ^a   Folgueira, Maria Aparecida Azevedo Koike ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto Brasileiro de Controle do Câncer IBCC   (Brazil)

^c UNIVERSITY AT ALBANY   (United States)

^d A C CAMARGO CANCER CENTER   (Brazil)

^e INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

Breast cancer; Calcitriol; Gene expression; Organotypic culture

Indexed keywords

CALCITRIOL; VITAMIN D RECEPTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BREAST CANCER; CA2 GENE; CELL LINEAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CYP24A1 GENE; DPP4 GENE; DRUG EFFICACY; EFTUD1 GENE; FEMALE; FIBROBLAST; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; KCNK3 GENE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TKTL1 GENE; UPREGULATION; VALIDATION PROCESS; WESTERN BLOTTING;

BREAST NEOPLASMS; CALCITRIOL; CARCINOMA, DUCTAL, BREAST; DOWN-REGULATION; EPITHELIAL CELLS; FEMALE; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA; STATISTICS, NONPARAMETRIC; TISSUE CULTURE TECHNIQUES; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; UP-REGULATION; VITAMINS;

EID: 84874931429     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-119     Document Type: Article

References (58)

1. Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, Colston KW. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 2005, 41(8):1164-1169. 10.1016/j.ejca.2005.01.017, 15911240.
2. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(8):1991-1997. 10.1158/1055-9965.EPI-04-0722, 16103450.
3. Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, Chang-Claude J. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large case-control study. Carcinogenesis 2008, 29(1):93-99.
4. Crew KD, Gammon MD, Steck SE, Hershman DL, Cremers S, Dworakowski E, Shane E, Terry MB, Desai M, Teitelbaum SL. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila) 2009, 2(6):598-604.
5. Yao S, Sucheston LE, Millen AE, Johnson CS, Trump DL, Nesline MK, Davis W, Hong CC, McCann SE, Hwang H. Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PLoS One 2011, 6(2):e17251. 10.1371/journal.pone.0017251, 3046139, 21386992.
6. Janowsky EC, Lester GE, Weinberg CR, Millikan RC, Schildkraut JM, Garrett PA, Hulka BS. Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr 1999, 2(1):283-291.
7. de Lyra EC, da Silva IA, Katayama ML, Brentani MM, Nonogaki S, Goes JC, Folgueira MA. 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer. J Steroid Biochem Mol Biol 2006, 100(4-5):184-192.
8. Mawer EB, Walls J, Howell A, Davies M, Ratcliffe WA, Bundred NJ. Serum 1,25-dihydroxyvitamin D May Be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab 1997, 82(1):118-122. 10.1210/jc.82.1.118, 8989244.
9. Palmieri C, MacGregor T, Girgis S, Vigushin D. Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol 2006, 59(12):1334-1336. 10.1136/jcp.2006.042747, 1860540, 17046848.
10. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009, 27(23):3757-3763. 10.1200/JCO.2008.20.0725, 19451439.
11. Eisman JA, Barkla DH, Tutton PJM. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D 3. Cancer Res 1987, 47:21-25.
12. Pourgholami MH, Akhter J, Lu Y, Morris DL. In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3. Cancer Lett 2000, 151:97-102. 10.1016/S0304-3835(99)00416-4, 10766428.
13. Peng X, Hawthorne M, Vaishnav A, St-Arnaud R, Mehta RG. 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res Treat 2009, 113(1):31-41. 10.1007/s10549-008-9900-0, 2695979, 18205042.
14. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan MJ, Margolis KL, Ockene JK, Phillips L, Pottern L. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006, 354(7):684-696. 10.1056/NEJMoa055222, 16481636.
15. Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O'Sullivan MJ, Yasmeen S. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 2008, 100(22):1581-1591. 10.1093/jnci/djn360, 2673920, 19001601.
16. Garland CF, French CB, Baggerly LL, Heaney R. Vitamin D supplement doses and serum 25-hydroxyvitamin D in the range associated with cancer prevention. Anticancer Res 2011, 31:607-611.
17. Bower M, Colston KW, Stein RC, Hedley A, Gazet JC, Ford HT, Coombes RC. Topical calcipotriol treatment in advanced breast cancer. Lancet 1991, 337:701-702. 10.1016/0140-6736(91)90280-3, 1672178.
18. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007, 25(6):669-674. 10.1200/JCO.2006.06.8197, 17308271.
19. Smith DC, Johnson CS, Freeman CC, Muindi J, Wilson JW, Trump DL. A Phase I Trial of Calcitriol (1,25-Dihydroxycholecalciferol) in Patients with Advanced Malignancy. Clin Cancer Res 1999, 5:2431-2439.
20. Beer TM, Munar M, Henner WD. A phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 2001, 91(12):2431-2439. 10.1002/1097-0142(20010615)91:12<2431::AID-CNCR1278>3.0.CO;2-3, 11413535.
21. G-JCMvd B, Pols HAP, Leeuwen JPTM. Anti-Tumor Effects of 1,25-Dihydroxyvitamin D3 and Vitamin D Analogs. Curr Pharm Des 2000, 6:717-732. 10.2174/1381612003400498, 10828303.
22. Nakagawa K, Sasaki Y, Kato S, Kubodera N, Okano T. 22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 2005, 26(6):1044-1054. 10.1093/carcin/bgi049, 15718253.
23. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1α,25-Dihydroxyvitamin D3 Inhibits Angiogenesis In Vitro and In Vivo. Circ Res 2000, 87:214-220. 10.1161/01.RES.87.3.214, 10926872.
24. Swami S, Raghavachari N, Muller UR, Bao YP, Feldman D. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNAmicroarray. Breast Cancer Res Treat 2003, 80:49-62. 10.1023/A:1024487118457, 12889598.
25. Barbosa EM, Nonogaki S, Katayama ML, Folgueira MA, Alves VF, Brentani MM. Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture. Virchows Arch 2004, 444(2):175-182. 10.1007/s00428-003-0929-5, 14652754.
26. Wu G, Fan RS, Li W, Ko TC, Brattain MG. Modulation of cell Cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene 1997, 15:155-1563.
27. Verlinden L, Verstuyf A, Convents R, Marcelis S, Camp MV, Bouillon R. Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endo 1998, 142:57-65.
28. Jensen SS, Mandsen MW, Lukas J, Binderup L, Bartek J. Inhibitory Effects of 1,25-Dihydroxyvitamin D3 on the G1-S Phase-Controlling Machinery. Mol Endocrinol 2001, 15(8):1370-1380. 10.1210/me.15.8.1370, 11463860.
29. Koli K, Keski-Oja J. 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor β1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res 1995, 55:1540-1546.
30. Wu G, Fan RS, Li W, Srinivas V, Brattain MG. Regulation of transforming growth factor-BetaType II receptor expression in human breast cancer MCF-7 cells by vitamin D3 and its analogues. J Biol Chem 1998, 273(13):7749-7756. 10.1074/jbc.273.13.7749, 9516484.
31. Katayama MLH, Pasini FS, Folgueira MAAK, Snitcovsky IML, Brentani MM. Molecular targets of 1,25(OH)2D3 in HC11 normal mouse mammary cell line. J Steroid Biochem Mol Biol 2003, 84(1):57-69. 10.1016/S0960-0760(03)00004-9, 12648525.
32. Bortman P, Folgueira MAAK, Katayama ML, Snitcovsky IML, Brentani MM. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells - A mini review. Braz J Med Biol Res 2002, 35(1):1-9.
33. Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL, Schmitt F. Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer 2010, 10:483. 10.1186/1471-2407-10-483, 2945944, 20831823.
34. Sobral RA, Honda ST, Katayama ML, Brentani H, Brentani MM, Patrao DF, Folgueira MA. Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer. Acta Vet Scand 2008, 50:27. 10.1186/1751-0147-50-27, 2474627, 18601734.
35. Milani C, Welsh J, Katayama ML, Lyra EC, Maciel MS, Brentani MM, Folgueira MA. Human breast tumor slices: a model for identification of vitamin D regulated genes in the tumor microenvironment. J Steroid Biochem Mol Biol 2010, 121(1-2):151-155.
36. Gache C, Berthois Y, Cvitkovic E, Martin P, Saez S. Differential regulation of normal and tumoral breast epithelial cell growth by fibroblasts and 1,25-dihydroxyvitaminD3. Breast Cancer Res Treat 1999, 55:29-39. 10.1023/A:1006163418479, 10472777.
37. Rozenchan PB, Carraro DM, Brentani H, de Carvalho Mota LD, Bastos EP, e Ferreira EN, Torres CH, Katayama ML, Roela RA, Lyra EC. Reciprocal changes in gene expression profiles of cocultured breast epithelial cells and primary fibroblasts. Int J Cancer 2009, 125(12):2767-2777. 10.1002/ijc.24646, 19530251.
38. Santos RP, Benvenuti TT, Honda ST, Del Valle PR, Katayama ML, Brentani HP, Carraro DM, Rozenchan PB, Brentani MM, de Lyra EC. Influence of the interaction between nodal fibroblast and breast cancer cells on gene expression. Tumour Biol 2011, 32(1):145-157. 10.1007/s13277-010-0108-7, 3003151, 20820980.
39. Hidalgo AA, Montecinos VP, Paredes R, Godoy AS, McNerney EM, Tovar H, Pantoja D, Johnson C, Trump D, Onate SA. Biochemical characterization of nuclear receptors for vitamin D3 and glucocorticoids in prostate stroma cell microenvironment. Biochem Biophys Res Commun 2011, 412(1):13-19. 10.1016/j.bbrc.2011.06.181, 21763285.
40. Campos LT, Brentani H, Roela RA, Katayama ML, Lima L, Rolim CF, Milani C, Folgueira MA, Brentani MM. Differences in transcriptional effects of 1α,25 dihydroxyvitamin D3 on fibroblasts associated to breast carcinomas and from paired normal breast tissues. J Steroid Biochem Mol Biol 2013, 133:12-24.
41. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 2009, 37:W305-311. 10.1093/nar/gkp427, 2703978, 19465376.
42. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545-15550. 10.1073/pnas.0506580102, 1239896, 16199517.
43. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y, Bourdeau V, Konstorum A, Lallemant B, Zhang R. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005, 19(11):2685-2695. 10.1210/me.2005-0106, 16002434.
44. Kovalenko PL, Zhang Z, Cui M, Clinton SK, Fleet JC. 1,25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics 2010, 13:11-26.
45. Ramagopalan SV, Heger A, Berlanga AJ, Maugeri NJ, Lincoln MR, Burrell A, Handunnetthi L, Handel AE, Disanto G, Orton SM. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res 2010, 20(10):1352-1360. 10.1101/gr.107920.110, 2945184, 20736230.
46. Shalhoub V, Shatzen EM, Ward SC, Young JI, Boedigheimer M, Twehues L, McNinch J, Scully S, Twomey B, Baker D. Chondro/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcitriol or paricalcitol. J Cell Biochem 2010, 111(4):911-921. 10.1002/jcb.22779, 3470918, 20665672.
47. Yu DM, Yao TW, Chowdhury S, Nadvi NA, Osborne B, Church WB, McCaughan GW, Gorrell MD. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 2010, 277(5):1126-1144. 10.1111/j.1742-4658.2009.07526.x, 20074209.
48. Biskobing DM, Fan D, Fan X, Rubin J. Induction of carbonic anhydrase II expression in osteoclast progenitors requires physical contact with stromal cells. Endocrinology 1997, 138(11):4852-4857. 10.1210/en.138.11.4852, 9348215.
49. Quelo I, Machuca I, Jurdic P. Identification of a vitamin D response element in the proximal promoter of the chicken carbonic anhydrase II gene. J Biol Chem 1998, 273(17):10638-10646. 10.1074/jbc.273.17.10638, 9553126.
50. Swami S, Krishnan AV, Wang JY, Jensen K, Horst R, Albertelli MA, Feldman D. Dietary vitamin D3 and 1,25-dihydroxyvitamin D3 (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology 2012, 153(6):2576-87. 10.1210/en.2011-1600, 22454149.
51. Matthews D, LaPorta E, Zinser GM, Narvaez CJ, Welsh J. Genomic vitamin D signaling in breast cancer: Insights from animal models and human cells. J Steroid Biochem Mol Biol 2010, 121(1-2):362-367. 2906670, 20412854.
52. Kemmis CM, Welsh JE. Mammary epithelial cell transformation is associated with deregulation of the vitamin D pathway. J Cell Biochem 2008, 105:980-988. 10.1002/jcb.21896, 2859445, 18767073.
53. Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H. Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res 2004, 10(19):6418-6431. 10.1158/1078-0432.CCR-04-1031, 15475428.
54. Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, Rutgers EJ, Rodenhuis S, van de Vijver MJ. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005, 23(15):3331-3342. 10.1200/JCO.2005.09.077, 15908647.
55. Folgueira MAAK, Brentani H, Carraro DM, Barros MD, Katayama MLH, De Abreu APS, Barbosa EM, De Oliveira CT, Patrao DFC, Mota LD. Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy. Oncol Rep 2009, 22(4):805-813.
56. Lee HJ, Liu H, Goodman C, Ji Y, Maehr H, Uskokovic M, Notterman D, Reiss M, Suh N. Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer. Biochem Pharmacol 2006, 72(3):332-343. 10.1016/j.bcp.2006.04.030, 16737686.
57. Towsend K, Trevino V, Falciani F, Stewart PM, Hewison M, Campbell MJ. Identification of VDR-responsive gene signatures in breast cancer cells. Oncology 2006, 71(1-2):111-123.
58. Schauber J, Oda Y, Buchau AS, Yun QC, Steinmeyer A, Zugel U, Bikle DD, Gallo RL. Histone acetylation in keratinocytes enables control of the expression of cathelicidin and CD14 by 1,25-dihydroxyvitamin D3. J Invest Dermatol 2008, 128(4):816-824. 10.1038/sj.jid.5701102, 17943182.